GlassScriptPhysician profile
Jenna M King-Sona
NPI 1679864375
$3,824.10
in general payments reported to CMS, 2019-2025
24 companies · $884 in 2025
The $884 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $51.84 · 2021: $15.41 · 2022: $455 · 2023: $932 · 2024: $1,242 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,893 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,893.03 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,092.80 | 2019-2025 | Otezla, Enbrel, Tavneos |
| Abbvie INC. | $615.29 | 2022-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $275.57 | 2022-2025 | Tremfya |
| Ucb, INC. | $259.79 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $212.44 | 2023-2025 | |
| Sandoz INC. | $203.36 | 2023-2025 | Hyrimoz, Jubbonti |
| Aurinia Pharma U.S., INC. | $189.40 | 2022-2025 | Lupkynis |
| Pfizer INC. | $142.53 | 2022-2025 | |
| Genentech USA, INC. | $128.10 | 2023-2025 | Actemra |
| Glaxosmithkline, LLC. | $109.54 | 2022-2025 | Benlysta |
| Genzyme Corporation | $86.21 | 2023-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $83.32 | 2024 | Arcalyst |
| Organon LLC | $62.48 | 2023-2024 | Hadlima |
| Lilly USA, LLC | $58.49 | 2019-2024 | Taltz |
| Ani Pharmaceuticals, INC. | $47.73 | 2025 | Purified Cortrophin Gel |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $46.06 | 2022-2024 | |
| Radius Health, INC. | $45.46 | 2023-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.47 | 2023-2024 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $31.14 | 2019-2024 | |
| Celgene Corporation | $30.12 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $20.08 | 2023 | Sohonos |
| Fresenius Kabi USA, LLC | $16.21 | 2025 | |
| Tonix Medicines, INC. | $16.06 | 2025 | Tonmya |
| Novartis Pharmaceuticals Corporation | $14.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna King-Sona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.